This systematic review provides an estimate of the pooled effect of semaglutide on BP in patients with obesity but without diabetes. Of note, the mean BP of cohorts in the included studies was in the normal range at baseline.

Dec 3, 2024 · Semaglutide’s ability to improve insulin sensitivity and lower glucose levels may also contribute to healthier blood pressure levels, possibly through improvements in endothelial function and reductions in arterial stiffness.

Oct 14, 2024 · This analysis shows a consistent 5 mm Hg SBP drop in patients on semaglutide nearly regardless of their starting BP. It is well-accepted that BP medications, in general, provide a greater SBP lowering effect on patients with higher BP compared to lower BPs.

Jan 18, 2023 · The effect of semaglutide in those with obesity and hypertension is as yet undetermined. Targeting excess body weight may be a novel therapeutic strategy for these patients. Keywords: STEP trials; blood pressure; body weight; glucagon-like peptide-1 receptor agonists; hypertension; obesity; randomized controlled trials; semaglutide; weight loss.

6 days ago · In fact, research suggests that semaglutide can help lower blood pressure.One review of studies found that people who took Ozempic noticed a 5 mmHg decrease in their systolic blood pressure (top number) on average. Other studies also found that semaglutide lowered people’s blood pressure and improved other factors that affect heart health.. There’s also evidence that semaglutide can ...

Jan 7, 2025 · Ozempic (semaglutide) is a blood sugar-lowering medication prescribed for people with type 2 diabetes. But it does more than help keep your blood sugar in check. One of its key benefits is weight...

Nov 11, 2024 · Semaglutide generally exhibited consistent benefits for CV outcomes regardless of history of HT or baseline BP categories (Figure). Compared with placebo, semaglutide significantly and consistently reduced systolic BP (SBP) across BP categories (normal, −2.9 [95% CI−4.0; −1.9]; elevated BP, −2.8 [−4.0; −1.6]; stage 1, −3.4: [−4. ...

Jan 18, 2023 · There is now high-quality evidence to suggest that semaglutide results in a clinically significant reduction in BP in these trial cohorts, which had a mean baseline BP in the normal range. It is likely that the BP-lowering effect of semaglutide in those who are hypertensive is likely greater than the 4.83 mmHg reported here, but the true effect ...

Dec 15, 2023 · To evaluate the blood pressure (BP) lowering ability of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), in individuals with type-2 diabetes (T2D).

Randomized clinical trials (RCTs) assessing semaglutide reported reductions of systolic blood pressure (SBP) in trial populations with baseline blood pressure in the normotensive range. This study aimed to determine whether this SBP reduction is greater in hypertensive groups.